Status and phase
Conditions
Treatments
About
This is an open-label, 2-Part, phase 1 study to evaluate drug interactions when DA-8010 is co-administered with Paroxetine or Mirabegron in healthy adult subjects
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
37 participants in 1 patient group
Loading...
Central trial contact
Seung Hwan Lee, PhD; Hyunwook Ryu
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal